Vistagen Announces Topline And Post-HOC Data From Palisade-4 Phase 3 Public Speaking Challenge Trial Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder

VistaGen Therapeutics Inc NASDAQ:VTGN:

• VISTAGEN ANNOUNCES TOPLINE AND POST-HOC DATA FROM PALISADE-4 PHASE 3 PUBLIC SPEAKING CHALLENGE TRIAL OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER

• VISTAGEN THERAPEUTICS INC: FASEDIENOL DID NOT ACHIEVE STATISTICALLY SIGNIFICANT IMPROVEMENT ON PRIMARY AND SECONDARY ENDPOINTS

• VISTAGEN THERAPEUTICS INC: FAVORABLE SAFETY AND TOLERABILITY DATA WERE CONSISTENT WITH PREVIOUS CLINICAL TRIALS

• VISTAGEN THERAPEUTICS - PLANS TO MEET WITH FDA ON REGISTRATION PATHWAY FOR FASEDIENOL WITH FUTURE PHASE 3 TRIAL

• VISTAGEN THERAPEUTICS - POST-HOC ANALYSIS SHOWS NOMINAL STATISTICAL SIGNIFICANCE FOR FASEDIENOL IN VERY SEVERE SOCIAL ANXIETY SUBGROUP